

Synonym

IGFBP-3 R, TMEM219, Insulin-like growth factor-binding protein 3 receptor, Transmembrane protein 219

Source

Human IGFBP-3 R, Fc Tag(IGR-H5259) is expressed from human 293 cells (HEK293). It contains AA Ser 39 - Arg 204 (Accession # [Q86XT9-1](#)).

Molecular Characterization

IGFBP3R(Ser 39 - Arg 204) Q86XT9-1	Fc(Pro 100 - Lys 330) P01857
---------------------------------------	---------------------------------

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 44.3 kDa. The protein migrates as 58-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human IGFBP-3 R, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS



The purity of Human IGFBP-3 R, Fc Tag (Cat. No. IGR-H5259) is more than 85% and the molecular weight of this protein is around 100-120 kDa verified by SEC-MALS.

[Report](#)

Background

IGFBP-3 R, also known as TMEM219, is a cell death receptor specific for IGFBP3. IGFBP-3R is expressed on the cell surface, interacts specifically with IGFBP-3 but not other IGFBP species. It activates initiator caspase-8, and mediates IGFBP-3-induced apoptosis in vitro and tumor suppression in vivo.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.